Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.48 |
| ▸ | NTRK1 known ✓ | P04629 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | DCUN1D1 | Q96GG9 | 9/20 | 0.49 |
| ▸ | UBE2M | P61081 | 8/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9263610 | 0.99 | ALDH1A1 (0.51) | ALDH1A1DCUN1D1UBE2MROCK2SMN1; SMN2 | |
| SCHEMBL9256240 | 0.95 | ALDH1A1 (0.47) | ALDH1A1DCUN1D1UBE2MROCK2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9256917 | 0.90 | DCUN1D1 (0.60) | ALDH1A1DCUN1D1UBE2MATMTP53 | |
| SCHEMBL10587275 | 0.89 | DCUN1D1 (0.61) | ALDH1A1DCUN1D1UBE2MATMTP53 | |
| SCHEMBL9257297 | 0.87 | DCUN1D1 (0.56) | ALDH1A1DCUN1D1UBE2MROCK2SMN1; SMN2 | |
| SCHEMBL9255607 | 0.87 | ALDH1A1 (0.53) | ALDH1A1DCUN1D1UBE2MROCK2SMN1; SMN2 | |
| SCHEMBL9261691 | 0.87 | ALDH1A1 (0.53) | ALDH1A1DCUN1D1UBE2MROCK2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9262873 | 0.86 | ALDH1A1 (0.52) | ALDH1A1DCUN1D1UBE2MROCK2SMN1; SMN2 | |
| SCHEMBL9260667 | 0.86 | ALDH1A1 (0.54) | ALDH1A1DCUN1D1UBE2MROCK2SMN1; SMN2 | |
| SCHEMBL9256017 | 0.86 | ALDH1A1 (0.66) | ALDH1A1DCUN1D1UBE2MSMN1; SMN2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024098005-A1 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR | EFIL BioScience Inc. (KR) | 2024-05-10 | — | — | WO | claimed |
| US-20240148833-A1 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR | EFIL BioScience Inc. (KR) | 2024-05-09 | — | — | US | claimed |
| US-20230302021-A1 | COMPOSITIONS AND METHODS FOR TREATING CASTRATION-RESISTANT PROSTATE CANCER | PURDUE RESEARCH FOUNDATION | 2023-09-28 | — | — | US | claimed |
| WO-2023183843-A1 | COMBINATION THERAPY FOR TREATING CASTRATION-RESISTANT PROSTATE CANCER | PURDUE RESEARCH FOUNDATION (US) | 2023-09-28 | — | — | WO | claimed |
| US-20230285333-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING FOOD INTAKE OF ANIMAL | PURDUE RESEARCH FOUNDATION | 2023-09-14 | — | — | US | claimed |
| US-20230270702-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPEPHAGIA | PURDUE RESEARCH FOUNDATION | 2023-08-31 | — | — | US | claimed |
| US-20260091010-A1 | COMPOSITIONS AND METHODS FOR MANAGING REBOUND OF BODY WEIGHT AND METABOLIC PARAMETERS | EFIL BIOSCIENCE INC (KR) | 2026-04-02 | — | — | US | disclosed |
| US-12274682-B2 | Compositions and methods for controlling food intake of animal | PURDUE RESEARCH FOUNDATION (US) | 2025-04-15 | — | — | US | disclosed |
| US-12274681-B2 | Compositions and methods for reducing skin fat | PURDUE RESEARCH FOUNDATION (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4525833-A2 | VETERINARY PHARMACEUTICAL FORMULATIONS | Increvet, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| US-12257217-B2 | Compositions and methods for treating hyperphagia in prader-willi syndrome | PURDUE RESEARCH FOUNDATION (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2024098005-A1 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR | EFIL BioScience Inc. (KR) | 2024-05-10 | — | — | WO | disclosed |
| US-20240148833-A1 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR | EFIL BioScience Inc. (KR) | 2024-05-09 | — | — | US | disclosed |
| US-20050118226-A1 | Sustained-release implant releases ACAT inhibitor for a time effective to reduce ACAT activity; Alzheimer's disease, atherosclerosis; amyloid- beta reduction | GENERAL HOSPITAL CORPORATION, THE | 2005-06-02 | — | — | US | disclosed |
| US-5405873-A | Antilipemic, anticholesterol agents; treating arterio-sclerosis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0587430-A1 | Substituted acetamide derivatives for treatment of hypocholesterolaemia, hyperlipaemia and arteriosclerosis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-03-16 | — | — | EP | disclosed |
| EP-0325397-B1 | DIUREA DERIVATIVES USEFUL AS MEDICAMENTS AND PROCESSES FOR THE PREPARATION THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1993-08-18 | — | — | EP | disclosed |
| US-5227492-A | Anticholesterol agents | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1993-07-13 | — | — | US | disclosed |
| US-5166429-A | Enzyme inhibitors of acylcoenzyme A cholesterol transferase as anticholesterol agents or antideposit agents | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1992-11-24 | — | — | US | disclosed |
| US-5091419-A | Anticholesterol agent | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1992-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12257217-B2 | Compositions and methods for treating hyperphagia in prader-willi syndrome | ACAT2, ACAT1, LCAT | ROCK2 1806/4885NTRK1 3884/4885ALDH1A1 1172/4885 |
| US-12274681-B2 | Compositions and methods for reducing skin fat | ACAT1, ACAT2, ACACA | ROCK2 1955/4885NTRK1 4861/4885ALDH1A1 476/4885 |
| US-20230270702-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPEPHAGIA | ACAT2, ACAT1, LCAT | ROCK2 2349/4885NTRK1 3821/4885ALDH1A1 1999/4885 |
| US-20230285333-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING FOOD INTAKE OF ANIMAL | ACAT2, ACAT1, LCAT | ROCK2 2901/4885NTRK1 4876/4885ALDH1A1 846/4885 |
| US-12274682-B2 | Compositions and methods for controlling food intake of animal | ACAT2, ACAT1, LCAT | ROCK2 2901/4885NTRK1 4876/4885ALDH1A1 846/4885 |
| US-20260091010-A1 | COMPOSITIONS AND METHODS FOR MANAGING REBOUND OF BODY WEIGHT AND METABOLIC PARAMETERS | GLP1R, GPR119, FABP4 | ROCK2 342/4885NTRK1 643/4885ALDH1A1 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.